You are here: Industry Insights > msd

News List

Incyte/MSD's immunotherapy combo fails in Phase III pharmatimes
April 10, 2018
A late stage trial testing Incyte’s epacadostat in combination with MSD’s Keytruda has failed to hit its primary targets in patients with unresectable or metastatic melanoma.
Eisai and MSD team up to combine Lenvima and Keytruda in cancer pharmafile
March 09, 2018
Pharma Heavyweight MSD (Merck) and Eisai announced that they will jointly develop the latter's tyrosine kinase inhibitor Lenvima (lenvatinib mesylate)
MSD, Ferring complete clinical trial for Postpartum Haemorrhage biospectrumasia
March 05, 2018
Excessive bleeding after childbirth (postpartum haemorrhage or PPH) is the leading direct cause of maternal mortality worldwide.
EU clears MSD’s Prevymis for CMV prevention pharmatimes
January 31, 2018
European regulators have approved MSD’s Prevymis for the prevention of cytomegalovirus (CMV) reactivation and disease in prone adults who have received an allogeneic haematopoietic stem cell transplant (HSCT).
EMA committee recommends seven therapies from Roche, GSK, MSD and more pharmafile
January 30, 2018
The European Medicines Agency’s Committee for Medicinal Products for Human Use has voiced its recommendation of a raft of products in a number of therapeutic areas, including candidates from GlaxoSmithKline, Roche and MSD.
MSD’s interim Keytruda combo data spooks Roche and BMS pharmafile
January 17, 2018
When PD-1/L1 treatments first came on the market, there was a race to snaffle as many indications as possible for the therapies
MSD launches Clostridium difficile antitoxin in the UK pharmatimes
January 11, 2018
MSD has launched Zinplava in the UK, offering patients a novel therapeutic option for the prevention of Clostridium difficile recurrence.
NICE backs wider use of MSD’s Simponi pharmatimes
January 11, 2018
Cost regulators for therapies funded by the NHS in England and Wales have added MSD’s Simponi (golimumab) to the list of treatments recommended for severe non-radiographic axial spondyloarthritis.
MSD, Wayra UK launch third Velocity Health programme pharmatimes
December 06, 2017
Merck Sharp & Dohme and Telefonica's Wayra UK have unveiled the next focus of their digital health innovation accelerator programme, calling on tech start-ups to "re-imagine healthcare" with the help of artificial intelligence and machine learning.
Samsung Biologics reinforces biologic manufacturing and development partnership with MSD pharmafile
October 31, 2017
Samsung Biologics has announced it has expanded its strategic alliance with MSD, or Merck as it is known in the US and Canada, with the signing of a memorandum of understanding

Previous page 1 2 3 4 5 6 7 8 9 10 11 Next page